Urenco Annual Report 2022

Urenco Annual report and accounts 2022 Our strategy 01 Case Study Around two million patient treatments benefit from Urenco Stable Isotopes After opening our new Leonardo da Vinci (LDV) cascade in 2021, Urenco Stable Isotopes has expanded its capacity. In 2023 we are planning to increase this further to enhance and diversify the supply for these important products. Designed for the enrichment of multiple isotopes – including those of germanium, xenon, selenium and silicon – the facility has enabled Urenco to increase its supply of stable isotopes for medical, industrial and research purposes. Stable isotopes have been produced for over three decades at Almelo, the Netherlands and the volume of our annual sales equate to approximately two million patient treatments being performed with medical products that have utilised or contain them. For example, Xenon 129 is used in MRI imaging to detect lung diseases. Xenon 124 is used to produce radioactive Iodine 123. This is then used in hospitals to detect thyroid issues and is also used in the diagnosis of Parkinson’s disease. Other applications are varied and include products for superfast computer processing power.We are looking forward to working with customers on new projects, producing high quality, cost-efficient solutions that will change lives. In the medical sector, Urenco enriched stable isotopes products make a valuable contribution to lifesaving patient treatments for serious diseases like cancer. Ensure healthy lives and promote well-being for all at all ages. 12 UN Sustainable Development Goals Main image: Stable Isotopes lab in Almelo,the Netherlands.